# Daily Online Adaptation Versus Localization for MRI-Guided SBRT for Unresectable Primary or Oligometastatic Abdominal Malignancies

> **NCT02950025** · PHASE2 · TERMINATED · sponsor: **Washington University School of Medicine** · enrollment: 5 (actual)

## Conditions studied

- Pancreatic Cancer
- Pancreas Cancer
- Cancer of the Pancreas
- Hepatocellular Carcinoma

## Interventions

- **DEVICE:** Online, adaptive MR-guided SBRT
- **DEVICE:** Online, non-adaptive MR-guided SBRT
- **OTHER:** European Organization for Research and Treatment of Cancer (EORTC) QLQ-30

## Key facts

- **NCT ID:** NCT02950025
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-01-19
- **Primary completion:** 2018-03-19
- **Final completion:** 2018-03-19
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Low accrual
- **Last updated:** 2019-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02950025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02950025, "Daily Online Adaptation Versus Localization for MRI-Guided SBRT for Unresectable Primary or Oligometastatic Abdominal Malignancies". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT02950025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*